Recent trends in the use of "club drugs": An Australian review

Substance Use and Misuse

Volumn 40, Issue 9-10, 2005, Pages 1241-1256

  Degenhardt, Louisa ^a   Copeland, Jan ^a   Dillon, Paul ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Club drugs; Ecstasy; Epidemiology; GHB; Ketamine; MDMA

Indexed keywords

1,4 BUTANEDIOL; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXYBUTYRIC ACID; 4 METHOXYAMPHETAMINE; ALCOHOL; AMPHETAMINE DERIVATIVE; ANESTHETIC AGENT; CANNABIS; COCAINE; DEXTROMETHORPHAN; GAMMA BUTYROLACTONE; ILLICIT DRUG; KETAMINE; LYSERGIDE; NEUROTOXIN; SEROTONIN; SEROTONIN RECEPTOR;

ACCIDENTAL DEATH; AGE DISTRIBUTION; AGGRESSION; ANOREXIA; ANXIETY DISORDER; AUSTRALIA; BEHAVIOR DISORDER; BRUXISM; COGNITIVE DEFECT; DEPRESSION; DRUG ALCOHOL INTERACTION; DRUG DEPENDENCE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG UTILIZATION; FATIGUE; HALLUCINATION; HEALTH HAZARD; HEALTH SURVEY; HUMAN; HYPERTHERMIA; HYPONATREMIA; INSOMNIA; INTRAVENOUS DRUG ABUSE; IRRITABILITY; MANIA; MENTAL DISEASE; MORTALITY; MUSCLE CRAMP; NAUSEA; NEUROTOXICITY; NIGHTMARE; NONHUMAN; PANIC; PARANOIA; PERSONALITY DISORDER; POPULATION RESEARCH; POSTTRAUMATIC STRESS DISORDER; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEXUAL BEHAVIOR; SIDE EFFECT; SOCIAL CLASS; SPEECH DISORDER; SUICIDAL BEHAVIOR; TACHYCARDIA; TIC; TREMOR; UNCONSCIOUSNESS; VISUAL IMPAIRMENT; WEIGHT REDUCTION; WITHDRAWAL SYNDROME;

EID: 23244437808     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.1081/JA-200066777     Document Type: Review

References (108)

1. ABCI (2000). Australian Illicit Drug Report 1998-1999. Canberra: Australian Bureau of Criminal Intelligence.
2. Abraham, M., Kaal, H., Cohen, P. (2002). Licit and Illicit Drug Use in the Netherlands 2001. Amsterdam: CEDRO/Mets en Schilt.
3. Ahmed, S. N., Petchovsky, L. (1980). Abuse of ketamine (Letter). British Journal of Psychiatry 137:303.
4. Aust, R. (2002). Prevalence of Drug Use: Key Findings from the 2001/2002 British Crime Survey. Home Office, London.
5. Australian Bureau of Criminal Intelligence (1995). Australian Illicit Drug Report 1994. Australian Bureau of Criminal Intelligence, Canberra.
6. Australian Bureau of Criminal Intelligence (2000). Australian Illicit Drug Report 1998-1999. Australian Bureau of Criminal Intelligence, Canberra.
7. Australian Institute of Health and Welfare (2002). 2001 National Drug Strategy Household Survey: First results. Australian Institute of Health (Drug Statistics Series), Canberra.
8. Beardsley, P. M., Balster, R. L. (1987). Behavioral dependence upon phencyclidine and ketamine in the rat. Journal of Pharmacology and Experimental Therapeutics 242:203-211.
9. Beck, F., Iegleye, S., Peretti-Watel, P. (2003). Survey EROPP 2002. Paris: OFDT.
10. Bobes, J., Saiz, P. A., Gonzalez, M. P., Bascaran, M. T., Bousono, M., Ricaurte, G. A., McCann, U. D. (2002). Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study. European Addiction Research 8:147-54.
11. Bowles, T., Sommi, R., Amiri, M. (2001). Successful management of prolonged gammahydroxybutyrate and alcohol withdrawal. Pharmacotherapy 21:254-257.
12. Boys, A., Marsden, J., Griffiths, P., Fountain, J., Stillwell, G., Strang, J. (1999). Substance use among young people: The relationship between perceived functions and intentions. Addiction 94:1043-1050.
13. Breen, C., Degenhardt, L., White, B., Bruno, R., Chanteloup, F., Fischer, J., Moon, C., Proudfoot, P., Richards, J., Ward, J., Weekley, J. (2004). Australian Party Drug Trends 2003. National Drug and Alcohol Research Centre, University of NSW, Sydney.
14. Breen, C., Topp, L., Longo, M. (2002). Adapting the IDRS methodology to monitor trends in party drug markets: Findings of a two-year Feasibility trial. National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
15. Brown, L. P. (1995). Pulse Check: National Trends in drug Abuse. Office of National Drug Control Policy, Washington.
16. Budisavljevic, M. N., Stewart, L., Sahn, S. A., Ploth, D. W. (2003). Hyponatremia associated with 3,4-methylenedioxymethylamphetamine ("ecstasy") abuse. American Journal of the Medical Sciences 326:89-93.
17. Buffum, J., Moser, C. (1986). MDMA and human sexual function. Journal of Psychoactive Drugs 18:355-359.
18. Catalano, M., Glass, J., Catalano, G., Burrows, S., Lynn, W., Weitzner, B. (2001). Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics 42:83-88.
19. Centre for Addiction and Mental Health (2003). Drug use among Ontario students, 1977-2003. Centre for Addiction and Mental Health, Ontario.
20. Chin, M., Kreutzer, R., Dyer, J. (1992). Acute poisoning from gamma-hydroxybutyrate overdose. Annals of Emergency Medicine 31:716-722.
21. Craig, K., Gomez, H., McManus, J., Bania, T. (2000). Severe gamma-hydroxybutyrate withdrawal: A case report and literature review. Journal of Emergency Medicine 18:65-70.
22. Crysell, A. (1998). Lost in the K-hole. In: Muzik, Vol. 40, pp. 45-48.
23. Curran, V., Monaghan, L. (2001). In and out of the K-hole-a comparison of the acute and residual effects of ketamine in frequent and infrequent ketamine users. Addiction 95:749-760.
24. Curran, V., Morgan, C. (2000). Cognitive, dissociative and psychogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 95:575-590.
25. Dalgarno, P. J., Shewan, D. (1996). Illicit use of ketamine in Scotland. Journal of Psychoactive Drugs 28:191-199.
26. Darke, S., Ross, J., Hando, J., Hall, W., Degenhardt, L. (2000). Illicit Drug Use in Australia: Monograph Series No. 43. National Drug and Alcohol Research Centre.
27. Degenhardt, L., Barker, B., Topp, L. (2004). Patterns of ecstasy use in Australia: Findings from a national household survey. Addiction 99:187-195.
28. Degenhardt, L., Darke, S., Dillon, P. (2002). GHB use among Australians: Characteristics, use patterns, and associated harm. Drug and Alcohol Dependence 67:89-94.
29. Degenhardt, L., Darke, S., Dillon, P. (2003). The prevalence and correlates of GHB overdose among Australian users. Addiction 98:199-204.
30. Dillon, P., Copeland, J., Jansen, K. L. R. (2003). Patterns of use and harms associated with non-medical ketamine use. Drug and Alcohol Dependence 69:23-28.
31. Dotson, J. W., Ackerman, D. L., West, L. J. (1995). Ketamine abuse. Journal of Drug Issues 25:751-757.
32. Drug Enforcement Agency (1997). Ketamine abuse increasing. Drug Enforcement Agency.
33. Dyer, J., Roth, B., Hyme, B. (2001). Gamma-hydroxybutyrate withdrawal syndrome. Annals of Emergency Medicine 37:147-153.
34. Eckstein, M., Henderson, S., DelaCruz, P., Newton, E. (1999). Gamma hydroxybutyrate (GHB): report of a mass intoxication and review of the literature. Preshospital Emergency Care 3:357-361.
35. Ferrara, S., Tedeschi, L., Frison, G. (1995). Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. Journal of Forensic Science 40:501-504.
36. Forsyth, A. J. M., Barnard, M., McKeganey, N. P. (1997). Musical preference as an indicator of adolescent drug use. Addiction 92:1317-1325.
37. Friedman, J., Westlake, R., Furman, M. (1996). "Grievous bodily harm": Gamma hydroxybutyrate abuse leading to the Wernicke-Korsakoff syndrome. Neurology 46:469-471.
38. Galloway, G., Frederick, S., Staggers, F., Gonzales, M., Stalcup, S., Smith, D. (1997). Gamma-hydroxybutyrate: An emerging drug of abuse that causes physical dependency. Addiction 92:89-96.
39. Gill, J. R., Stajic, M. (2000). Ketamine in non-hospital and hospital deaths in New York City. Journal of Forensic Science 45:655-658.
40. Gowing, L. R., Henry-Edwards, S. M., Irvine, R. J., Ali, R. L. (2002). The health effects of ecstasy: A literature review. Drug & Alcohol Review. 21:53-63.
41. Griffiths, P., Gossop, M., Powis, B., Strang, J. (1993). Reaching hidden populations of drug users by privileged access interviewers: Methodological and practical issues. Addiction 88:1617-1626.
42. Gross, S. R., Barrett, S. P., Shestowsky, J. S., Pihl, R. O. (2002). Ecstasy and drug consumption patterns: A Canadian rave population study. Canadian Journal of Psychiatry-Revue Canadienne de Psychiatrie. 47:546-51.
43. Hammersley, R., Ditton, J., Smith, I., Short, E. (1999). Patterns of ecstasy use by drug users. British Journal of Criminology 39:625-647.
44. Hurt, P. H., Ritchie, E. C. (1994). A case of ketamine dependence (Letter). American Journal of Psychiatry 151:779.
45. Ingels, M., Rangan, C., Bellezo, J., Clark, R. (2000). Coma and respiratory depression following the ingestion of GHB and its precursors: Three cases. Journal of Emergency Medicine 19:47-50.
46. Jansen, K. L. R. (1990). Ketamine: Can chronic use impair memory? International Journal of Addictions 25:133-139.
47. Jansen, K. L. R. (1993). Non-medical use of ketamine (Editorial). British Medical Journal 306:601-602.
48. Jansen, K. L. R. (2000). Ketamine, Dreams and Realities. Sarasota, Florida: Multidisciplinary Association for Psychedelic Studies.
49. Johnston, L. D., O'Malley, P. M., Bachman, J. G. (2003). National Survey Results on Drug Use from the Monitoring the Future Study, 1975-2003, Rockville, MD: National Institute on Drug Abuse.
50. Kamaya, H., Krishna, P. R. (1987). Ketamine addiction (Letter). Anaesthesia 67:861-862.
51. Karch, S., Stephens, B., Nazareno, G. (2001). GHB: Club drug or confusing artifact? American Journal of Forensic Medicine and Pathology 22:268-269.
52. Kent, J. (1996). The Ketamine Konundrum. http://www.lycaeum.org/~lux/ alchem/konunb.1 accessed 6/25/97.
53. Kerlinger, F. N. (1986). Foundations of Behavioral Research. Tokyo, Japan: CBS Publishing Limited.
54. Klitzman, R., Greenberg, J., Pollack, L., Dolezal, C. (2002). MDMA ('ecstasy') use, and its association with high risk behaviours, mental health, and other factors among gay/bisexual men in New York City. Drug & Alcohol Dependence 66:115-125.
55. Koesters, S. C., Rogers, P. D., Rajasingham, C. R. (2002). MDMA ('ecstasy') and other 'club drugs.' The new epidemic. The Pediatric Clinics of North America 49:415-433.
56. Li, J., Stokes, S., Woeckener, A. (1998). A tale of novel intoxication: Seven cases of gamma-hydroxybutyrate acid overdose. Annals of Emergency Medicine 31:723-728.
57. Lieb, R., Schuetz, C. G., Pfister, H., von Sydow, K., Wittchen, H. (2002). Mental disorders in ecstasy users: A prospective-longitudinal investigation. Drug & Alcohol Dependence. 68:195-207.
58. Lilly, J. C. (1978). The Scietist: A Novel Autobiography. New York: Bantam Books, Lippincourt.
59. Mansergh, G., Colfax, G. N., Marks, G., Rader, M., Guzman, R., Buchbinder, S. (2001). The Circuit Party Men's Health Survey: Findings and implications for gay and bisexual men. American Journal of Public Health 91:953-8.
60. McDaniel, C., Miotto, K. (2001). Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: Five case studies. Journal of Psychoactive Drugs 33:143-149.
61. McKetin, R., Darke, S., Humeniuk, R., Dwyer, R., Bruno, R., Fleming, J., Kinner, S., Hargreaves, K., Rysavy, P. (2000). Australian Drug Trends 1999. Findings from the Illicit Drug Reporting System (IDRS). NDARC Monograph No. 43. Sydney: National Drug and Alcohol Research Centre, UNSW.
62. Michael, G. W., Hall, J. N. (1994). South Florida at risk for Grievous Bodily Harm. Information for Action. Drug Surveillance News, May 9.
63. Miotto, K., Darakjian, J., Basch, J., Murray, S., Zogg, J., Rawson, R. (2001). Gammahydroxybutyric acid: Patterns of use, effects and withdrawal. American Journal on Addictions 10:232-241.
64. Miro, O., Nogue, S., Espinosa, G., To-Figueras, J., Sanchez, M. (2002). Trends in illicit drug emergencies: The emerging role of gamma-hydroxybutyrate. Journal of Toxicology-Clinical Toxicology 40:129-35.
65. Moore, N. N., Bostwick, J. M. (1999). Ketamine dependence in anesthesia providers. Psychosomatics 40:356-359.
66. Muller, A. (2003). GHB poisoning: Three recent cases reflect the continuing danger. Journal of Emergency Nursing 29:72-74.
67. National Advisory Committee on Drugs and Drug and Alcohol Information and Research Unit (2003). Drug use in Ireland and Northern Ireland: First results from the 2002/2003 drug prevalence survey.
68. National Plan on Drugs (2001). Household Survey on Drugs 2001. Spain.
69. New York State Office of Alcoholism and Substance Abuse Service (1997). Ketamine Update. Bureau of Applied Studies-Street Studies Unit, New York.
70. Nicholson, K., Balster, R. (2001). GHB: A new and novel drug of abuse. Drug and Alcohol Dependence 63:1-22.
71. Parke-Davis (1999-2000). Parke-Davis Product information Sheet: Ketalar. ABPI Compendium of Data Sheets and Summaries of Product Characteristics. Datapharm Publications.
72. Parrott, A. C., Buchanan, T., Scholey, A. B., Heffernan, T., Ling, J., Rodgers, J. (2002). Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Human Psychopharmacology 17:309-312.
73. Parrott, A. C., Milani, R. M., Parmar, R., Turner, J. D. (2001). Recreational ecstasy/MDMA and other drug users from the UK and Italy: Psychiatric symptoms and psychobiological problems. Psychopharmacology. 159:77-82.
74. Pierce, P. A., Peroutka, S. (1988). Ring-substituted amphetamine interactions with neurotransmitter receptor binding sites in human cortex. Neuroscience Letters 95:208-212.
75. Sanguineti, V., Angelo, A., Frank, M. (1997). GHB: A home brew. American Journal of Drug & Alcohol Abuse 23:637-642.
76. Schneir, A., Ly, B., Clark, R. (2001). A case of withdrawal from the GHB precursors gammabutyrolactone and 1,4-butanediol. Journal of Emergency Medicine 21:31-33.
77. Sherlock, K., Wolff, K., Hay, A., Conner, M. (1999). Analysis of illicit ecstasy tablets: Implications for clinical management in the accident and emergency department. Journal of Accident & Emergency Medicine 16(3): 194-197.
78. Skovmand, K. (1996). Swedes alarmed at ketamine misuse. The Lancet 348:122.
79. Solowij, N., Hall, W., Lee, N. (1992). Recreational MDMA use in Sydney: A profile of 'ecstacy' users and their experiences with the drug. British Journal of Addiction 87:1161-1172.
80. Soyka, M., Krupinski, G., Volki, G. (1993). Phenomenology of ketamine induced psychosis. Sucht 5:327-331.
81. Sprague, J., Everman, S., Nichols, D. (1998). An integrated hypothesis for the serotonergic axonal loss induced by 3,4-methylenedioxymethamphetamine. Neurotoxicology 19:427-441.
82. Sputz, R. (1989). I never met a reality I did not like: A report on 'vitamin K'. In: High Times, Vol. October, pp. 64-82.
83. Strote, J., Lee, J. E., Wechsler, H. (2002). Increasing MDMA use among college students: Results of a national survey. Journal of Adolescent Health 30:64-72.
84. Substance Abuse and Mental Health Services Administration (2002). Results from the 2001 National Household Survey on Drug Abuse: Volume I. Summary of National Findings. Rockville, MD: SAMHSA, US Department of Health and Human Services.
85. Thomas, G., Bonner, S., Gascoigne, A. (1997). Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): A case report. British Medical Journal 314:35.
86. Topp, L., Barker, B., Degenhardt, L. (2004). The external validity of results derived from ecstasy users recruited using purposive sampling strategies. Drug & Alcohol Dependence 73:33-40.
87. Topp, L., Breen, C., Kaye, S., Darke, S. (2002a). NSW Party Drug Trends 2001. Findings from the Illicit Drug Reporting System (IDRS) Party Drugs Module. NDARC technical report No. 136. National Drug and Alcohol Research Centre, UNSW, Sydney: NSW
88. Topp, L., Darke, S. (2001). NSW Party Drug Trends 2000: Findings of the illicit Drug Reporting System Party Drugs Module. National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
89. Topp, L., Hando, J., Degenhardt, L., Dillon, P., Roche, A., Solowij, N. (1997). Ecstasy Use in Australia. NDARC Monograph No. 39. National Drug and Alcohol Research Centre, Sydney.
90. Topp, L., Hando, J., Degenhardt, L., Dillon, P., Roche, A., Solowij, N. (1998). Ecstasy use in Australia. Monograph No. 39. National Drug and Alcohol Research Centre, Sydney.
91. Topp, L., Hando, J., Dillon, P., Roche, A., Solowij, N. (1999). Ecstasy use in Australia: Patterns of use and associated harm. Drug and Alcohol Dependence 55:105-115.
92. Topp, L., Kaye, S., Bruno, R., Hargreaves, K., Longo, M., Williams, P., O'Reilly, B., Fry, C., Rose, G., Darke, S. (2002b). Australian Drug Trends 2001: Findings of the Illicit Drug Reporting System (IDRS). NDARC Monograph No. 48. National Drug and Alcohol Research Centre, UNSW., Sydney.
93. Tori, S. P. (1996). Ketamine Abuse. 'Special K.' Middle Atlantic-Great Lakes Organized Crime Law Enforcement Network (MAGLOCLEN), Pennsylvania.
94. Turner, D. M. (1994). The Essential Guide to Psychedelics. Frederick, MD: Panther Press.
95. United States Department of Health and Human Services (1997). Gamma hydroxybutyrate use-New York and Texas, 1995-1996. Morbidity and Mortality Weekly Report 46:281-283.
96. U.S. Drug Enforcement Agency (2001). Drug Intelligence Brief-Club Drugs: An Update. Vol. 2002 DEA Intelligence Division, Office of Domestic Intelligence, Domestic Strategy Unit.
97. von Sydow, K., Lieb, R., Pfister, H., Hofler, M., Wittchen, H. U. (2002). Use, abuse and dependence of ecstasy and related drugs in adolescents and young adults-a transient phenomenon? Results from a longitudinal community study. Drug & Alcohol Dependence. 66:147-59.
98. Weiner, A. L., Vieira, L., Mckay, C. A., Bayer, M. J. (2000). Ketamine abusers presenting to the Emergency Department: A case series. Journal of Emergency Medicine 18:447-451.
99. Weir, E. (2000). Raves: A review of the culture, the drugs and the prevention of harm. Canadian Medical Association Journal 162:1843-1848.
100. White, B., Breen C., Degenhardt, L. (2003). New South Wales Party Drugs Trends 2002: Findings from the Illicit Drug Reporting System (IDRS) Party Drugs Module. National Drug and Alcohol Research Centre, University of New South Wales, Sydney.
101. White, B., Breen, C., Degenhardt, L. (2004). New South Wales Party Drug Trends 2003: Findings of the Party Drugs Initiative. National Drug and Alcohol Research Centre, University of NSW, Sydney.
102. White, J. M., Bochner, F., Irvine, R. J. (1997). The agony of "ecstasy"-How can we avoid more "ecstasy"-related deaths? MJA 166:117.
103. White, J. M., Ryan, C. F. (1996). Pharmacological properties of ketamine. Drug and Alcohol Review 15:145-155.
104. Whitten, L. (2001). Conference highlights increasing GHB abuse. NIDA Notes 16:10-11.
105. Wilkins, C., Casswell, S., Bhatta, K., Pledger, M. (2002). Drug use in New Zealand: National surveys comparison 1998 and 2001. Alcohol and Public Health Research Unit, Auckland.
106. Williamson, S., Gossop, M., Powis, B., Griffiths, P., Fountain, J., Strang, J. (1997). Adverse effects of stimulant drugs in a community sample of drug users. Drug and Alcohol Dependence 44:87-94.
107. Winstock, A. R., Griffiths, P., Stewart, D. (2001). Drugs and the dance music scene: A survey of current drug use patterns among a sample of dance music enthusiasts in the UK. Drug & Alcohol Dependence. 64:9-17.
108. Zemishlany, Z., Aizenberg, D., Weizman, A. (2001). Subjective effects of MDMA ('ecstasy') on human sexual function. European Psychiatry 16:127-130.